07:45 AM EDT, 05/14/2026 (MT Newswires) -- Fennec Pharmaceuticals ( FENC ) , up 12.6% in U.S. pre-market trading, Thursday reported a swing to a first-quarter profit as sales of Pedmark surged.

The company, which developed Pedmark or sodium thiosulfate injection, to reduce the risk of cisplatin-induced hearing loss in pediatric patients, reported a profit of US$0.2 million, or US$0.01 per share, compared with a loss of US$1.2 million, or US$0.04 per share, in the prior year period. Analysts polled by FactSet had forecast a loss of US$0.04 per share.

Fennec booked net product sales of US$15.1 million, compared with US$8.8 million last year. Analysts had expected US$13.9 million. The increase is due to growth across Pedmark accounts, including new accounts in the adolescent and young adult (AYA) population. Demand in the first quarter was driven by prescribing in three core tumor types: testicular, cervical and head and neck cancers, and these remain foundational to Fennec's commercial opportunity, Fennec said.

"We are encouraged by our continued quarter-over-quarter growth and strong start to the year. 2026 is a defining period for Fennec, with growing clinical interest in independently evaluating PEDMARK(r) (sodium thiosulfate injection) across new patient populations and tumor types that reinforces our confidence in its broader potential," said Jeff Hackman, chief executive officer.

Fennec Pharmaceuticals ( FENC ) was last seen up US$0.85, to US$7.62 in New York trading. It closed down $0.30, to $9.28, on the Toronto Stock Exchange.